Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Durect Corporation is a drug manufacturers-specialty & generic business based in the US. Durect Corporation shares (DRRX) are listed on the NASDAQ and all prices are listed in US Dollars. Durect Corporation employs 78 staff and has a trailing 12-month revenue of around $13.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.59 |
|---|---|
| 52-week range | $0.36 - $1.32 |
| 50-day moving average | $0.65 |
| 200-day moving average | $0.62 |
| Wall St. target price | $5.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.16 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.59 from 2022-10-03
| 1 week (2022-09-28) | 5.34% |
|---|---|
| 1 month (2022-09-02) | -18.06% |
| 3 months (2022-07-05) | 28.26% |
| 6 months (2022-04-04) | 1.72% |
| 1 year (2021-10-05) | -50.00% |
|---|---|
| 2 years (2020-10-05) | -68.78% |
| 3 years (2019-10-04) | 1.87 |
| 5 years (2017-10-04) | 1.99 |
| Revenue TTM | $13.5 million |
|---|---|
| Gross profit TTM | $-19,824,000 |
| Return on assets TTM | -26.54% |
| Return on equity TTM | -71.49% |
| Profit margin | -292.71% |
| Book value | $0.16 |
| Market capitalisation | $134.3 million |
TTM: trailing 12 months
We're not expecting Durect Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Durect Corporation's shares have ranged in value from as little as $0.36 up to $1.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Durect Corporation's is 1.1998. This would suggest that Durect Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd. ; and Santen Pharmaceutical Co.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.